Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis

Ilaria Ceglia, Amylou Dueck, Francesca Masiello, Fabrizio Martelli, Wu He, Giulia Federici, Emanuel F. Petricoin, Ann Zeuner, Camelia Iancu-Rubin, Rona Weinberg, Ronald Hoffman, John Mascarenhas, Anna Rita Migliaccio

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

To assess the role of abnormal transforming growth factor-beta (TGF-β) signaling in the pathogenesis of primary myelofibrosis (PMF), the effects of the TGF-β receptor-1 kinase inhibitor SB431542 on ex vivo expansion of hematopoietic cells in cultures from patients with JAK2V617+-polycythemia vera (PV) or PMF (JAK2V617F+, CALRpQ365f+, or unknown) and from normal sources (adult blood, AB, or cord blood, CB) were compared. In cultures of normal sources, SB431542 significantly increased by 2.5-fold the number of progenitor cells generated by days 1–2 (CD34+) and 6 (colony-forming cells) (CB) and that of precursor cells, mostly immature erythroblasts, by days 14–17 (AB and CB). In cultures of JAK2V617F+-PV, SB431542 increased by twofold the numbers of progenitor cells by day 10 and had no effect on that of precursors cells by days 12–17 (∼fourfold increase in all cases). In contrast, SB431542 had no effect on the number of either progenitor or precursor cells in cultures of JAK2V617F+ and CALR pQ365fs+ PMF. These ontogenetic- and disease-specific effects were associated with variegation in the ability of SB431542 to induce CD34+ cells from AB (increased), CB (decreased), or PV and PMF (unaffected) into cycle and erythroblasts in proliferation (increased for AB and PV and unaffected for CB and PMF). Differences in expansion of erythroblasts from AB, CB, and PV were associated with differences in activation of TGF-β signaling (SHCY317, SMAD2S245/250/255, and SMAD1S/S/SMAD5S/S/SMAD8S/S) detectable in these cells by phosphoproteomic profiling. In conclusion, treatment with TGF-β receptor-1 kinase inhibitors may reactivate normal hematopoiesis in PMF patients, providing a proliferative advantage over the unresponsive malignant clone.

Original languageEnglish (US)
Pages (from-to)1138-1155
Number of pages18
JournalExperimental Hematology
Volume44
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Primary Myelofibrosis
Polycythemia Vera
Transforming Growth Factor beta
Erythroblasts
Phosphotransferases
Stem Cells
Therapeutics
Cell Culture Techniques
Hematopoiesis
Fetal Blood
Clone Cells
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Genetics
  • Cell Biology
  • Cancer Research

Cite this

Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis. / Ceglia, Ilaria; Dueck, Amylou; Masiello, Francesca; Martelli, Fabrizio; He, Wu; Federici, Giulia; Petricoin, Emanuel F.; Zeuner, Ann; Iancu-Rubin, Camelia; Weinberg, Rona; Hoffman, Ronald; Mascarenhas, John; Migliaccio, Anna Rita.

In: Experimental Hematology, Vol. 44, No. 12, 01.12.2016, p. 1138-1155.

Research output: Contribution to journalArticle

Ceglia, I, Dueck, A, Masiello, F, Martelli, F, He, W, Federici, G, Petricoin, EF, Zeuner, A, Iancu-Rubin, C, Weinberg, R, Hoffman, R, Mascarenhas, J & Migliaccio, AR 2016, 'Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis', Experimental Hematology, vol. 44, no. 12, pp. 1138-1155. https://doi.org/10.1016/j.exphem.2016.08.007
Ceglia, Ilaria ; Dueck, Amylou ; Masiello, Francesca ; Martelli, Fabrizio ; He, Wu ; Federici, Giulia ; Petricoin, Emanuel F. ; Zeuner, Ann ; Iancu-Rubin, Camelia ; Weinberg, Rona ; Hoffman, Ronald ; Mascarenhas, John ; Migliaccio, Anna Rita. / Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis. In: Experimental Hematology. 2016 ; Vol. 44, No. 12. pp. 1138-1155.
@article{7a5ff390cfb74d66bd4db776e762de3e,
title = "Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis",
abstract = "To assess the role of abnormal transforming growth factor-beta (TGF-β) signaling in the pathogenesis of primary myelofibrosis (PMF), the effects of the TGF-β receptor-1 kinase inhibitor SB431542 on ex vivo expansion of hematopoietic cells in cultures from patients with JAK2V617+-polycythemia vera (PV) or PMF (JAK2V617F+, CALRpQ365f+, or unknown) and from normal sources (adult blood, AB, or cord blood, CB) were compared. In cultures of normal sources, SB431542 significantly increased by 2.5-fold the number of progenitor cells generated by days 1–2 (CD34+) and 6 (colony-forming cells) (CB) and that of precursor cells, mostly immature erythroblasts, by days 14–17 (AB and CB). In cultures of JAK2V617F+-PV, SB431542 increased by twofold the numbers of progenitor cells by day 10 and had no effect on that of precursors cells by days 12–17 (∼fourfold increase in all cases). In contrast, SB431542 had no effect on the number of either progenitor or precursor cells in cultures of JAK2V617F+ and CALR pQ365fs+ PMF. These ontogenetic- and disease-specific effects were associated with variegation in the ability of SB431542 to induce CD34+ cells from AB (increased), CB (decreased), or PV and PMF (unaffected) into cycle and erythroblasts in proliferation (increased for AB and PV and unaffected for CB and PMF). Differences in expansion of erythroblasts from AB, CB, and PV were associated with differences in activation of TGF-β signaling (SHCY317, SMAD2S245/250/255, and SMAD1S/S/SMAD5S/S/SMAD8S/S) detectable in these cells by phosphoproteomic profiling. In conclusion, treatment with TGF-β receptor-1 kinase inhibitors may reactivate normal hematopoiesis in PMF patients, providing a proliferative advantage over the unresponsive malignant clone.",
author = "Ilaria Ceglia and Amylou Dueck and Francesca Masiello and Fabrizio Martelli and Wu He and Giulia Federici and Petricoin, {Emanuel F.} and Ann Zeuner and Camelia Iancu-Rubin and Rona Weinberg and Ronald Hoffman and John Mascarenhas and Migliaccio, {Anna Rita}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.exphem.2016.08.007",
language = "English (US)",
volume = "44",
pages = "1138--1155",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis

AU - Ceglia, Ilaria

AU - Dueck, Amylou

AU - Masiello, Francesca

AU - Martelli, Fabrizio

AU - He, Wu

AU - Federici, Giulia

AU - Petricoin, Emanuel F.

AU - Zeuner, Ann

AU - Iancu-Rubin, Camelia

AU - Weinberg, Rona

AU - Hoffman, Ronald

AU - Mascarenhas, John

AU - Migliaccio, Anna Rita

PY - 2016/12/1

Y1 - 2016/12/1

N2 - To assess the role of abnormal transforming growth factor-beta (TGF-β) signaling in the pathogenesis of primary myelofibrosis (PMF), the effects of the TGF-β receptor-1 kinase inhibitor SB431542 on ex vivo expansion of hematopoietic cells in cultures from patients with JAK2V617+-polycythemia vera (PV) or PMF (JAK2V617F+, CALRpQ365f+, or unknown) and from normal sources (adult blood, AB, or cord blood, CB) were compared. In cultures of normal sources, SB431542 significantly increased by 2.5-fold the number of progenitor cells generated by days 1–2 (CD34+) and 6 (colony-forming cells) (CB) and that of precursor cells, mostly immature erythroblasts, by days 14–17 (AB and CB). In cultures of JAK2V617F+-PV, SB431542 increased by twofold the numbers of progenitor cells by day 10 and had no effect on that of precursors cells by days 12–17 (∼fourfold increase in all cases). In contrast, SB431542 had no effect on the number of either progenitor or precursor cells in cultures of JAK2V617F+ and CALR pQ365fs+ PMF. These ontogenetic- and disease-specific effects were associated with variegation in the ability of SB431542 to induce CD34+ cells from AB (increased), CB (decreased), or PV and PMF (unaffected) into cycle and erythroblasts in proliferation (increased for AB and PV and unaffected for CB and PMF). Differences in expansion of erythroblasts from AB, CB, and PV were associated with differences in activation of TGF-β signaling (SHCY317, SMAD2S245/250/255, and SMAD1S/S/SMAD5S/S/SMAD8S/S) detectable in these cells by phosphoproteomic profiling. In conclusion, treatment with TGF-β receptor-1 kinase inhibitors may reactivate normal hematopoiesis in PMF patients, providing a proliferative advantage over the unresponsive malignant clone.

AB - To assess the role of abnormal transforming growth factor-beta (TGF-β) signaling in the pathogenesis of primary myelofibrosis (PMF), the effects of the TGF-β receptor-1 kinase inhibitor SB431542 on ex vivo expansion of hematopoietic cells in cultures from patients with JAK2V617+-polycythemia vera (PV) or PMF (JAK2V617F+, CALRpQ365f+, or unknown) and from normal sources (adult blood, AB, or cord blood, CB) were compared. In cultures of normal sources, SB431542 significantly increased by 2.5-fold the number of progenitor cells generated by days 1–2 (CD34+) and 6 (colony-forming cells) (CB) and that of precursor cells, mostly immature erythroblasts, by days 14–17 (AB and CB). In cultures of JAK2V617F+-PV, SB431542 increased by twofold the numbers of progenitor cells by day 10 and had no effect on that of precursors cells by days 12–17 (∼fourfold increase in all cases). In contrast, SB431542 had no effect on the number of either progenitor or precursor cells in cultures of JAK2V617F+ and CALR pQ365fs+ PMF. These ontogenetic- and disease-specific effects were associated with variegation in the ability of SB431542 to induce CD34+ cells from AB (increased), CB (decreased), or PV and PMF (unaffected) into cycle and erythroblasts in proliferation (increased for AB and PV and unaffected for CB and PMF). Differences in expansion of erythroblasts from AB, CB, and PV were associated with differences in activation of TGF-β signaling (SHCY317, SMAD2S245/250/255, and SMAD1S/S/SMAD5S/S/SMAD8S/S) detectable in these cells by phosphoproteomic profiling. In conclusion, treatment with TGF-β receptor-1 kinase inhibitors may reactivate normal hematopoiesis in PMF patients, providing a proliferative advantage over the unresponsive malignant clone.

UR - http://www.scopus.com/inward/record.url?scp=84992208933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992208933&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2016.08.007

DO - 10.1016/j.exphem.2016.08.007

M3 - Article

C2 - 27592389

AN - SCOPUS:84992208933

VL - 44

SP - 1138

EP - 1155

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 12

ER -